{"entity":{"id":"platform-vs-personalized-components","kind":"term","name":"Platform and personalised components of a product","aka":["platform versus personalised components","shared and individual product components"],"tldr":"Some parts of a personalised treatment are reused for every recipient, such as the manufacturing process. Others are chosen for one person, such as the sequence of the vaccine or the person's own cells. Each actual batch still needs to be checked on its own.","summary":"Individualised products reuse some components and personalise others, and the two need separate evidence. In the phase 1 study of autogene cevumeran in resected pancreatic cancer (Rojas et al., 2023), individual vaccines of up to 20 neoantigens per patient were made in real time as uridine mRNA-lipoplex nanoparticles; 16 patients received atezolizumab and the vaccine, 15 subsequently received mFOLFIRINOX chemotherapy, and new neoantigen-specific T cells were detected in 8 of the 16 patients, and it shows one defined design carrying individual messages, not that all RNA vaccines share a recipe or outcome. In mice, a peptide-TLR-7/8a conjugate platform was built to self-assemble into nanoparticles of uniform size (about 20 nm) whatever the peptide, to address the physicochemical variability of neoantigens (Lynn et al., 2020). For autologous CAR T cells, FDA's 2024 guidance notes variability in the starting cells and recommends maintaining chain of identity from collection to administration, with at least two unique identifiers on labels of autologous products. A shared process and specification can support consistent handling and repeatable testing, but they do not establish that a new sequence or a changed process is equivalent to an earlier one, that a lot made for one recipient can be accepted on another recipient's results, or that the encoded targets are presented and recognised in a patient. 'Platform' here is a descriptive term for reuse, not a regulatory designation.","asOf":"2026-11-10","links":[{"label":"Rojas et al., 2023: personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","url":"https://doi.org/10.1038/s41586-023-06063-y"},{"label":"Lynn et al., 2020: peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly","url":"https://doi.org/10.1038/s41587-019-0390-x"},{"label":"FDA: considerations for the development of CAR T cell products (January 2024)","url":"https://www.fda.gov/media/156896/download"},{"label":"FDA: content and format of chemistry, manufacturing and controls information and establishment description information for a vaccine or related product (January 1999)","url":"https://www.fda.gov/media/73614/download"},{"label":"FDA: Platform Technology Designation Program for Drug Development (May 2024 draft)","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/platform-technology-designation-program-drug-development"}],"tags":[],"related":["neoantigen-mrna-vaccine","car-t-manufacturing-process","good-manufacturing-practice","batch-release"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The single question to ask: is this feature deliberately reused across recipients, or selected for this recipient? Personalisation may concern an antigen sequence, a receptor sequence, the person's own cells or a combination, and need not mean that every reagent or step is redesigned. The answer depends on the program.","Platform is a teaching description of reuse and not a regulatory designation or authorisation. Reuse can support consistent handling, shared process learning and repeatable testing, and the two sides commonly work together; neither wins on efficacy by itself.","Shared process evidence informs but does not replace lot-level evidence. Inference lesson: if recipients A and B share RNA features and formulation but carry different antigen messages, a lot made for A that passes identity and quality checks does not allow lot B to be accepted; B must match its own specification and meet its own applicable checks, with traceability.","Different kinds of personalisation. Rojas et al. (2023) made individual mRNA-lipoplex vaccines of up to 20 neoantigens in real time (phase 1: 16 received atezolizumab and vaccine, followed by mFOLFIRINOX in 15). Lynn et al. (2020) built peptide conjugates to self-assemble into nanoparticles of about 20 nm whatever the peptide, to address neoantigen variability in mice. FDA's 2024 CAR T guidance notes variability in starting cells and recommends maintaining chain of identity from collection to administration, with at least two unique identifiers on autologous product labels. An individually selected receptor and an individual's own cells are different personalisation.","Quality categories. FDA's 1999 vaccine CMC guidance asks for characterisation with respect to identity, purity, potency and stability; it is dated and scoped to vaccine applications, so it illustrates categories and is not a rulebook for every individualised modality. No universal personalised-product cutoff exists. Passing release criteria does not show that antigens were selected correctly, presented naturally or that treatment benefits people.","The FDA also uses Platform Technology Designation for a separate formal programme under section 506K. Its May 2024 draft guidance describes designation requests and eligibility factors. Shared components or a manufacturing recipe do not by themselves establish that designation; platform in this entry means the described reuse of product components."],"provenance":{"editedBy":"OnCo education audit","editedOn":"2026-11-10"},"category":"Treatment jargon"},"route":"/terms/platform-vs-personalized-components/","neighbours":{"technology":[{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"term":[{"id":"batch-release","kind":"term","name":"Batch release (lot disposition)","route":"/terms/batch-release/"},{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/"},{"id":"good-manufacturing-practice","kind":"term","name":"Good manufacturing practice (GMP)","route":"/terms/good-manufacturing-practice/"}]}}